Oxidative stress in diabetic nephropathy

Current Medicinal Chemistry

Volumn 17, Issue 34, 2010, Pages 4256-4269

  Kashihara, N ^a   Haruna, Y ^a   Kondeti, V K ^b   Kanwar, Y S ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diabetic nephropathy; Hyperglycemia; Reactive oxygen species; Renin angiotensin system

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARGININE; ASCORBIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; I KAPPA B BETA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTOSE PHOSPHATE; POLYOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SORBITOL; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ALBUMINURIA; AMINO ACID DEFICIENCY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CITRIC ACID CYCLE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; ESSENTIAL HYPERTENSION; HEMODYNAMIC PARAMETERS; HEMODYNAMIC STRESS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; REDOX STRESS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; RESPIRATORY CHAIN; SIGNAL TRANSDUCTION; SMOKING;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; NADPH OXIDASE; OXIDATIVE STRESS; RABBITS; RATS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 78650657305     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793348581     Document Type: Article

References (163)

1. Stamler, J.; Vaccaro, O.; Neaton, J. D.; Wenteworth, D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-444.
2. Haffner, S. M.; Lehto, S.; Ronnemaa, T.; Pyorala, K.; Lasskso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339, 229-234.
3. Ritz, E.; Rychlik, I.; Locatelli, F.; Halimi, S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am. J. Kidney Dis., 1999, 34, 795-808.
4. Bamashmus, M. A.; Matlhaga, B.; Dutton, G. N. Causes of blindness and visual impairment in the West of Scotland. Eye (Lond)., 2004, 18, 257-261.
5. Congdon, N.; O'Colmain, B.; Klaver, C. C.; Klein, R.; Munoz, B.; Friedman, D. S.; Kempen, J.; Taylor, H. R.; Mitchell, P. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol., 2004, 122, 477-485.
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med., 1993, 329, 977-986.
7. Holman, R. R.; Paul, S. K.; Bethel, M. A.; Matthews, D. R.; Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med., 2008, 359, 1577-1589.
8. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
9. Papaharalambus, C. A.; Griendling, K. K. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med., 2007, 17, 84-54.
10. Maiese, K.; Chong, Z. Z.; Shang, Y. C. Mechanistic insights into diabetes mellitus and oxidative stress. Curr. Med. Chem., 2007, 14, 1729-1738.
11. Forbes, J. M.; Coughlan, M. T.; Cooper, M. E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes, 2008, 57, 1446-1454.
12. Duchen, M. R. Roles of mitochondria in health and disease. Diabetes, 2004, 53 (Suppl 1), S96-102.
13. Baynes, J. W.; Thorpe, S. R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes, 1999, 48, 1-9.
14. Ceriello, A.; Morocutti, A.; Mercuri, F.; Quagliaro, L.; Moro, M.; Damante, G.; Viberti, G. C. Defective intracellular antioxidative enzyme production in type 1 diabetic patients with nephropathy. Diabetes, 2000, 49, 2170-2177.
15. Riemer, J.; Bulleid, N.; Herrmann, J. M. Disulfide formation in the ER and mitochondria: two solutions to a common process. Science, 2009, 324, 1284-1287.
16. Kowaltowski, A. J.; de Souza-Pinto, N. C.; Castilho, R. F.; Vercesi, A. E. Mitochondria and reactive oxygen species. Free Radic. Biol. Med., 2009, 47, 333-343.
17. Addabbo, F.; Montagnani, M.; Goligorsky, M. S. Mitochondria and reactive oxygen species. Hypertension, 2009, 53, 885-892.
18. Skulachev, V. P.; Anisimov, V. N.; Antonenko, Y. N.; Bakeeva, L. E.; Chernyak, B. V.; Erichev, V. P.; Filenko, O. F.; Kalinina, N. I.; Kapelko, V. I.; Kolosova, N. G.; Kopnin, B. P.; Korshunova, G. A.; Lichinitser, M. R.; Obukhova, L. A.; Pasyukova, E. G.; Pisarenko, O. I.; Roginsky, V. A.; Ruuge, E.k.; Senin, I. I.; Severina, I. I.; Skulachev, M. V.; Spivak, I. M.; Tashlitsky, V. N.; Tkachuk, V. A.; Vyssokikh, M. Y.; Yaguzhinsky, L. S.; Zorov, D. B. An attempt to prevent senescence: a mitochondrial approach. Biochim. Biophys. Acta., 2009, 1787, 437-461.
19. Esposito, L. A.; Melov, S.; Panov, A.; Cottrell, B. A.; Wallace, D. C. Mitochondrial disease in mouse results in increased oxidative stress. Proc. Natl. Acad. Sci. USA., 1999, 96, 4820-4825.
20. Lieber, M. R.; Karanjawala, Z. E. Ageing, repetitive genomes and DNA damage. Nat. Rev. Mol. Cell Biol., 2004, 5, 69-75.
21. Williams, R. S. Canaries in the coal mine: mitochondrial DNA and vascular injury from reactive oxygen species. Circ. Res., 2000, 86, 915-916.
22. Ide, T.; Tsutsui, H.; Hayashidani, S.; Kang, D.; Suematsu, N.; Nakamura, K.; Utsumi, H.; Hamasaki, N.; Takeshita, A. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ. Res., 2001, 88, 529-535.
23. Madamanchi, N. R.; Runge, M. S. Mitochondrial dysfunction in atherosclerosis. Circ. Res., 2007, 100, 460-473.
24. Gupte, S. A.; Levine, R. J.; Gupte, R. S.; Young, M. E.; Lionetti, V.; Labinskyy, V.; Floyd, B. C.; Ojaimi, C.; Bellomo, M.; Wolin, M. S.; Recchia, F. A. Glucose-6-phosphate dehydrogenase-derived NADPH fuels superoxide production in the failing heart. J. Mol. Cell Cardiol., 2006, 41, 340-349.
25. Greene, D. A.; Lattimer, S. A.; Sima, A. A. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med., 1987, 316, 599-606.
26. Williamson, J. R.; Chang, K.; Frangos, M.; Hasan, K. S.; Ido, Y.; Kawamura, T.; Nyengaard, J. R.; Van den Enden, M.; Kilo, C.; Tilton, R. G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 1993, 42, 801-813.
27. Raskin, P.; Rosenstock, J. Aldose reductase inhibitors and diabetic complications. Am. J. Med., 1987, 83, 298-306.
28. El-Benna, J.; Dang, P. M.; Gougerot-Pocidalo, M. A.; Marie, J. C.; Braut-Boucher, F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp. Mol. Med., 2009, 41, 217-225.
29. Dale, D. C.; Boxer, L.; Liles, W. C. The phagocytes: neutrophils and monocytes. Blood, 2008, 112, 935-945.
30. Nauseef, W. M. How human neutrophils kill and degrade microbes: an integrated view. Immunol. Rev., 2007, 219, 88-102.
31. Gill, P. S.; Wilcox, C. S. NADPH oxidases in the kidney. Antioxid. Redox. Signal., 2006, 8, 1597-1607.
32. Li, J. M.; Shah, A. M. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J. Am. Soc. Nephrol., 2003, 14, S221-226.
33. Zalba, G.; San Jose, G.; Moreno, M. U.; Fortuno, M. A.; Fortuno, A.; Beaumont, F. J.; Diez, J. Oxidative stress in arterial hypertension: role of NAD (P) H oxidase. Hypertension, 2001, 38, 1395-1399.
34. Yang, S.; Madyastha, P.; Bingel, S.; Ries, W.; Key, L. A new superoxide-generating oxidase in murine osteoclasts. J. Biol. Chem., 2001, 276, 5452-5458.
35. Jones, S. A.; Hancock, J. T.; Jones, O. T.; Neubauer, A.; Topley, N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J. Am. Soc. Nephrol., 1995, 5, 1483-1491.
36. Shiose, A.; Kuroda, J.; Tsuruya, K.; Hirai, M.; Hirakata, H.; Naito, S.; Hattori, M.; Sakaki, Y.; Sumimoto, H. A novel superoxideproducing NAD (P) H oxidase in kidney. J. Biol. Chem., 2001, 276, 1417-1423.
37. Radeke, H. H.; Cross, A. R.; Hancock, J. T.; Jones, O. T.; Nakamura, M.; Kaever, V.; Resch, K. Functional expression of NADPH oxidase components (alpha-and beta-subunits of cytochrome b558 and 45-kDa flavoprotein) by intrinsic human glomerular mesangial cells. J. Biol. Chem., 1991, 266, 21025-21029.
38. Ushio-Fukai, M. Vascular signaling through G protein-coupled receptors: new concepts. Curr. Opin. Nephrol. Hypertens., 2009, 18, 153-159.
39. Zafari, A. M.; Ushio-Fukai, M.; Akers, M.; Yin, Q.; Shah, A.; Harrison, D. G.; Taylor, W. R.; Griendling, K. K. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension, 1998, 32, 488-495.
40. Ushio-Fukai, M.; Zafari, A. M.; Fukui, T.; Ishizaka, N.; Griendling, K. K. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem., 1996, 271, 23317-23321.
41. Forstermann, U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 338-349.
42. Sachse, A.; Wolf, G. Angiotensin II-induced reactive oxygen species and the kidney. J. Am. Soc. Nephrol., 2007, 18, 2439-2446.
43. Ushio-Fukai, M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc. Res., 2006, 71, 226-235.
44. Collins, T.; Cybulsky, M. I. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest., 2001, 107, 255-264.
45. Asaba, K.; Tojo, A.; Onozato, M. L.; Goto, A.; Quinn, M. T.; Fujita, T.; Wilcox, C. S. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int., 2005, 67, 1890-1898.
46. Nam, S. M.; Lee, M. Y.; Koh, J. H.; Park, J. H.; Shin, J. Y.; Shin, Y. G.; Koh, S. B.; Lee, E. Y.; Chung, C. H. Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. Diabetes Res. Clin. Pract., 2009, 83, 176-182.
47. Thallas-Bonke, V.; Thorpe, S. R.; Coughlan, M. T.; Fukami, K.; Yap, F. Y.; Sourris, K. C.; Penfold, S. A.; Bach, L. A.; Cooper, M. E.; Forbes, J. M. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes, 2008, 57, 460-469.
48. Han, H. J.; Lee, Y. J.; Park, S. H.; Lee, J. H.; Taub, M. High glucoseinduced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. Am. J. Physiol. Renal Physiol., 2005, 288, F988-996.
49. Weichert, W.; Paliege, A.; Provoost, A. P.; Bachmann, S. Upregulation of juxtaglomerular NOS1 and COX-2 precedes glomerulosclerosis in fawn-hooded hypertensive rats. Am. J. Physiol. Renal Physiol., 2001, 280, F706-714.
50. Ishii, N.; Patel, K. P.; Lane, P. H.; Taylor, T.; Bian, K.; Murad, F.; Pollock, J. S.; Carmines, P. K. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J. Am. Soc. Nephrol., 2001, 12, 1630-1639.
51. Sullivan, J. C.; Pardieck, J. L.; Hyndman, K. A.; Pollock, J. S. Renal NOS activity, expression, and localization in male and female spontaneously hypertensive rats. Am. J. Physiol. Regul Integr. Comp. Physiol., 2010, 298, R61-69.
52. Kwon, N. S.; Nathan, C. F.; Stuehr, D. J. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J. Biol. Chem., 1989, 264, 20496-20501.
53. Tayeh, M. A.; Marletta, M. A. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J. Biol. Chem., 1989, 264, 19654-19658.
54. Stuehr, D. J.; Santolini, J.; Wang, Z. Q.; Wei, C. C.; Adak, S. Update on mechanism and catalytic regulation in the NO synthases. J. Biol. Chem., 2004, 279, 36167-36170.
55. Herrera, M.; Garvin, J. L. Recent advances in the regulation of nitric oxide in the kidney. Hypertension, 2005, 45, 1062-1067.
56. Maier, W.; Cosentino, F.; Lutolf, RB.; Fleisch, M.; Seiler, C.; Hess, O. M.; Meier, B.; Luscher, T. F. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J. Cardiovasc. Pharmacol., 2000, 35, 173-178.
57. Ueda, S.; Matsuoka, H.; Miyazaki, H.; Usui, M.; Okuda, S.; Imaizumi, T. Tetrahydrobiopterin restores endothelial function in longterm smokers. J. Am. Coll. Cardiol., 2000, 35, 71-75.
58. Pou, S.; Pou, W. S.; Bredt, D. S.; Synder, S. H.; Rosen, G. M. Generation of superoxide by purified brain nitric oxide synthase. J. Biol. Chem., 1992, 267, 24173-24176.
59. Cosentino, F.; Katusic, Z. S. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation, 1995, 91, 139-144.
60. Channon, K. M. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc. Med., 2004, 14, 323-327.
61. Crabtree, M. J.; Tatham, A. L.; Al-Wakeel, Y.; Warrick, N.; Hale, A. B.; Cai, S.; Channon, K. M.; Alp, N. J. Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin- eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J. Biol. Chem., 2009, 284, 1136-1144.
62. Moens, A. L.; Takimoto, E.; Tocchetti, C. G.; Chakir, K.; Bedja, D.; Cormaci, G.; Ketner, E. A.; Majmudar, M.; Gabrielson, K.; Halushka, M. K.; Mitchell, J. B.; Biswal, S.; Chinnon, K. M.; Wolin, M. S.; Alp, N. J.; Paolocci, N.; Champion, H. C.; Kass, D. A. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation, 2008, 117, 2626-2636.
63. Antoniades, C.; Shirodaria, C.; Crabtree, M.; Rinze, R.; Alp, N.; Cunnington, C.; Diesch, J.; Tousoulis, D.; Stefanadis, C.; Leeson, P.; Ratnatunga, C.; Pillai, R.; Channon, K. M. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation, 2007, 116, 2851-2859.
64. Komers, R.; Anderson, S. Paradoxes of nitric oxide in the diabetic kidney. Am. J. Physiol. Renal Physiol., 2003, 284, F1121-1137.
65. Rudberg, S.; Persson, B.; Dahlquist, G. Increased glomerular filtration rate as a predictor of diabetic nephropathy-an 8-year prospective study. Kidney Int., 1992, 41, 822-828.
66. Zatz, R.; Meyer, T. W.; Rennke, H. G.; Brenner, B. M. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc. Natl. Acad. Sci. USA., 1985, 82, 5963-5967.
67. De Vriese, A. S.; Stoenoiu, M. S.; Elger, M.; Devuyst, O.; Vanholder, R.; Kriz, W.; Lameire, N. H. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int., 2001, 60, 202-210.
68. Tolins, J. P.; Shultz, P. J.; Raij, L.; Brown, D. M.; Mauer, S. M. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am. J. Physiol., 1993, 265, F886-895.
69. Veelken, R.; Hilgers, K. F.; Hartner, A.; Haas, A.; Bohmer, K. P.; Sterzel, R. B. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol., 2000, 11, 71-79.
70. Omer, S.; Shan, J.; Varma, D. R.; Mulay, S. Augmentation of diabetes-associated renal hyperfiltration and nitric oxide production by pregnancy in rats. J. Endocrinol., 1999, 161, 15-23.
71. Komers, R.; Lindsley, J. N.; Oyama, T. T.; Allison, K. M.; Anderson, S. Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am. J. Physiol. Renal Physiol., 2000, 279, F573-583.
72. Komers, R.; Oyama, T. T.; Chapman, J. G.; Allison, K. M.; Anderson, S. Effects of systemic inhibition of neuronal nitric oxide synthase in diabetic rats. Hypertension, 2000, 35, 655-661.
73. Suto, T.; Losonczy, G.; Qiu, C.; Hill, C.; Samsell, L.; Ruby, J.; Charon, N.; Venuto, R.; Baylis, C. Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int., 1995, 48, 1272-1277.
74. Pieper, G. M. Enhanced, unaltered and impaired nitric oxidemediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia, 1999, 42, 204-213.
75. Moens, A. L.; Kass, D. A. Tetrahydrobiopterin and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2439-2444.
76. Vasquez-Vivar, J.; Hogg, N.; Martasek, P.; Karoui, H.; Pritchard, K. A. Jr.; Kalyanaraman, B. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J. Biol. Chem., 1999, 274, 26736-26742.
77. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B. S.; Karoui, H.; Tordo, P.; Pritchard, K. A. Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA., 1998, 95, 9220-9225.
78. Satoh, M.; Fujimoto, S.; Haruna. Y.; Arakawa, S.; Horike, H.; Komai, N.; Sasaki, T.; Tsujioka, K.; Makino, H.; Kashihara, N. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol., 2005, 288, F1144-1152.
79. Kawashima, S. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium, 2004, 11, 99-107.
80. Alp, N. J.; Mussa, S.; Khoo, J.; Cai, S.; Guzik, T.; Jefferson, A.; Goh, N.; Rockett, K. A.; Channon, K. M. Tetrahydrobiopterindependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest., 2003, 112, 725-735.
81. Cai, S.; Alp, N. J.; McDonald, D.; Smith, I.; Kay, J.; Canevari, L.; Heales, S.; Channon, K. M. GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerization. Cardiovasc. Res., 2002, 55, 838-849.
82. Heitzer, T.; Brockhoff, C.; Mayer, B.; Warnholtz, A.; Mollnau, H.; Henne, S.; Meinertz, T.; Munzel, T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ. Res., 2000, 86, E36-41.
83. Stroes, E.; Kastelein, J.; Cosentino, F.; Erkelens, W.; Wever, R.; Koomans, H.; Luscher, T.; Rabelink, T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest., 1997, 99, 41-46.
84. d'Uscio, L. V.; Milstien, S.; Richardson, D.; Smith, L.; Katusic, Z. S. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ. Res., 2003, 92, 88-95.
85. Verhaar, M. C.; Stroes, E.; Rabelink, T. J. Folates and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 6-13.
86. Hattori, Y.; Nakanishi, N.; Akimoto, K.; Yishida, M.; Kasai, K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 176-182.
87. Kuzkaya, N.; Weissmann, N.; Harrison, D. G.; Dikalov, S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J. Biol. Chem., 2003, 278, 22546-22554.
88. Landmesser, U.; Dikalov, S.; Price, S. R.; McCann, L.; Fukai, T.; Holland, S. M.; Mitch, W. E.; Harrison, D. G. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest., 2003, 111, 1201-1209.
89. Chalupsky, K.; Cai, H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA, 2005, 102, 9056-9061.
90. Xu, J.; Wu, Y.; Song, P.; Zhang, M.; Wang, S.; Zou, M. H. Proteasome-dependent degradation of guanosine 5'-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation, 2007, 116, 944-953.
91. Touyz, R. M. Reactive oxygen species as mediators of calcium signaling by angiotensin II: implications in vascular physiology and pathophysiology. Antioxid. Redox Signal., 2005, 7, 1302-1314.
92. Ogawa, S.; Mori, T.; Nako, K.; Kato, T.; Takeuchi, K.; Ito, S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension, 2006, 47, 699-705.
93. Fan, Q.; Liao, J.; Kobayashi, M.; Yamashita, M.; Gu, L.; Gohda, T.; Suzuki, Y.; Wang, L. N.; Horikoshi, S.; Tomino, Y. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol. Dial. Transplant., 2004, 19, 3012-3020.
94. Onozato, M. L.; Tojo, A.; Goto, A.; Fujita, T.; Wilcox, C. S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int., 2002, 61, 186-194.
95. Okumura, M.; Masada, M.; Yoshida, Y.; Shintaku, H.; Hosoi, M., Okada, N.; Konishi, Y.; Morikawa, T.; Miura, K.; Imanishi, M. Decrease in tetrahydrobiopterin as a possible cause of nephropathy in type II diabetic rats. Kidney Int., 2006, 70, 471-476.
96. Kosugi, T.; Nakayama, T.; Heinig, M.; Zhang, L.; Yuzawa, Y.; Sanchez-Lozada, L. G.; Roncal, C.; Johnson, R. J.; Nakagawa, T. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am. J. Physiol. Renal Physiol. 2009, 297, F481-488.
97. Matsumotom, S.; Koshiishi, I.; Inoguchi, T.; Nawata, H.; Utsumi, H. Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic. Res., 2003, 37, 767-772.
98. Cirillo, P.; Gersch, M. S.; Mu, W.; Scherer, P. M.; Kim, K. M.; Gesualdo, L.; Henderson, G. N.; Johnson, R. J.; Sautin, Y. Y. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. J. Am. Soc. Nephrol., 2009, 20, 545-553.
99. Bierhaus, A.; Hofmann, M. A.; Ziegler, R.; Nawroth, P. P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc. Res., 1998, 37, 586-600.
100. Jakus, V.; Rietbrock, N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res., 2004, 53, 131-142.
101. Schleicher, E. D.; Wagner, E.; Nerlich, A. G. Increased accumulation of the glycoxidation product N (epsilon) - (carboxymethyl) lysine in human tissues in diabetes and aging. J. Clin. Invest., 1997, 99, 457-468.
102. Kilhovd, B. K.; Berg, T. J.; Birkeland, K. I.; Thorsby, P.; Hanssen, K. F. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care, 1999, 22, 1543-1548.
103. Forbes, J. M.; Cooper, M. E.; Oldfield, M. D.; Thomas, M. C. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol., 2003, 14, S254-258.
104. Huebschmann, A. G.; Regensteiner, J. G.; Vlassara, H.; Reusch, J. E. Diabetes and advanced glycoxidation end products. Diabetes Care, 2006, 29, 1420-1432.
105. Ahmed, N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract., 2005, 67, 3-21.
106. Huang, J. S.; Guh, J. Y.; Chen, H. C.; Hung, W. C.; Lai, Y. H.; Chuang, L. Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell Biochem., 2001, 81, 102-113.
107. Cooper, M. E.; Thallas, V.; Forbes, J.; Scalbert, E.; Sastra, S.; Darby, I.; Soulis, T. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia, 2000, 43, 660-664.
108. Iacobini, C.; Menini, S.; Oddi, G.; Ricci, C.; Amadio, L.; Pricci, F.; Olivieri, A.; Sorcini, M.; Sorcini, M.; Di Mario, U.; Pesce, C.; Pugliese, G. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J., 2004, 18, 1773-1775.
109. Miyazaki, A., Nakayama, H.; Horiuchi, S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc. Med., 2002, 12, 258-262.
110. Neeper, M.; Schmidt, A. M.; Brett, J.; Yan, S. D.; Wang, F.; Pan, Y. C.; Elliston, K.; Stern, D.; Shaw, A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem., 1992, 267, 14998-15004.
111. Li, Y. M.; Mitsuhashi, T.; Wojciechowicz, D.; Shimizu, N.; Li, J.; Stitt, A.; He, C.; Banerjee, D.; Vlassara, H. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA., 1996, 93, 11047-11052.
112. Tooke, J. E. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J. Diabetes Complications. 2000, 14, 197-200.
113. Ceriello, A.; Bortolotti, N.; Pirisi, M.; Crescentini, A.; Tonutti, L.; Motz, E.; Russo, A.; Giacomello, R.; Stel, G.; Tobaga, C. Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care, 1997, 20, 1589-1593.
114. Ceriello, A.; Bortolotti, N.; Crescentini, A.; Motz, E.; Lizzio, S.; Russo, A.; Ezsol, Z.; Tonutti, L.; Toboga, C. Antioxidant defenses are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur. J. Clin. Invest., 1998, 28, 329-333.
115. Janssen-Heininger, Y. M.; Poynter, M. E.; Baeuerle, P. A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic. Biol. Med., 2000, 28, 1317-1327.
116. Luppi, P.; Cifarelli, V.; Tse, H.; Piganelli, J.; Trucco, M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia, 2008, 51, 1534-1543
117. Sanchez, A. P.; Sharma, K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med., 2009, 11, e13.
118. Gloire, G.; Legrand-Poels, S.; Piette, J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol., 2006, 72, 1493-1505.
119. Kabe, Y.; Ando, K.; Hirao, S.; Yoshida, M.; Handa, H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal., 2005, 7, 395-403.
120. Karin, M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J. Biol. Chem., 1999, 274, 27339-27342.
121. Li, N.; Karin, M. Is NF-kappaB the sensor of oxidative stress? FASEB J., 1999, 13, 1137-1143.
122. Burdon, R. H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med., 1995, 18, 775-794.
123. De Caterina, R.; Libby, P.; Peng, H. B.; Thannickal, V. J.; Rajavashisth, T. B.; Gimbrone, M. A. Jr.; Shin, W. S.; Liao, J. K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest., 1995, 96, 60-68.
124. Bao, X.; Lu, C.; Frangos, J. A. Temporal gradient in shear but not steady shear stress induces PDGF-A and MCP-1 expression in endothelial cells: role of NO, NF kappa B, and egr-1. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 996-1003.
125. Guzik, T. J.; Harrison, D. G. Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease? Circ. Res., 2007, 101, 227-229.
126. Hess, J.; Angel, P.; Schorpp-Kistner, M. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci., 2004, 117, 5965-5973.
127. McCubrey, J. A.; Lahair, M. M.; Franklin, R. A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal., 2006, 8, 1775-1789.
128. Kang, S. W.; Adler, S. G.; Lapage, J.; Natarajan, R. p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int., 2001, 60, 543-552.
129. Hostetter, T. H.; Rennke, H. G.; Brenner, B. M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am. J. Med., 1982, 72, 375-380.
130. Wiseman, M. J.; Mangili, R.; Alberetto, M.; Keen, H.; Viberti, G. Glomerular response mechanisms to glycemic changes in insulindependent diabetics. Kidney Int., 1987, 31, 1012-1018.
131. Woods, L. L.; Mizelle, H. L.; Hall, J. E. Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback. Am. J. Physiol. 1987, 252, F65-73.
132. Forster, H. G.; ter Wee, P. M.; Hohman, T. C.; Epstein, M. Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat. Diabetologia, 1996, 39, 907-914.
133. Zatz, R.; Dunn, B. R.; Meyer, T. W.; Anderson, S.; Rennke, H. G.; Brenner, B. M. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J. Clin. Invest., 1986, 77, 1925-1930.
134. Taguma, Y.; Kitamoto, Y.; Futaki, G.; Ueda, H.; Monma, H.; Ishizaki, M.; Takahashi, H.; Sekino, H.; Sasaki, Y. Effect of captopril on heavy proteinuria in azotemic diabetics. N. Engl. J. Med., 1985, 313, 1617-1620.
135. Lewis, E. J.; Hunsicker, L. G.; Bain, R. P.; Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med., 1993, 329, 1456-1462.
136. Ruggenenti, P.; Fassi, A.; Ilieva, A. P.; Bruno, S.; Iliev, I. P.; Brusegan, V.; Rubis, N.; Gherardi, G.; Arnoldi, F.; Ganeva, M.; Ene-Ioradache, B.; Gaspari, F.; Perna, A.; Bossi, A.; Trevisan, R.; Dodesini, A. R.; Remuzzi, G. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med., 2004, 351, 1941-1951.
137. Lewis, E. J.; Hunsicker, L. G.; Clarke, W. R.; Berl, T.; Pohl, M. A., Lewis, J. B.; Ritz, E.; Atkins, R. C.; Rohde, R.; Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
138. Brenner, B. M.; Cooper, M. E.; de Zeeuw, D.; Keane, W. F.; Mitch, W. E.; Parving, H. H.; Remuzzi, G.; Snapinn, S. M.; Zhang, Z.; Shahinfar, S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
139. Andersen, S.; Brochner-Mortensen, J.; Parving, H. H. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care, 2003, 26, 3296-3302.
140. Viberti, G.; Wheeldon, N. M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressureindependent effect. Circulation, 2002, 106, 672-678.
141. Ogawa, S.; Kobori, H.; Ohnasi, N.; Urushihara, M.; Nishiyama, A.; Mori, T.; Ishizuka, T.; Nako, K.; Ito, S. Angiotensin II type 1 receptor blockers reduce unrinary angiotensinogen excretion and levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark. Insights, 2009, 4, 97-102.
142. Anderson, S.; Jung, F. F.; Ingelfinger, J. R. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am. J. Physiol, 1993, 265, F477-486.
143. Singh, R.; Singh, A. K.; Alavi, N.; Leehey, D. J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J. Am. Soc. Nephrol, 2003, 14, 873-880.
144. Vidotti, D. B.; Casarini, D. E.; Cristovam, P. C.; Leite, C. A.; Schor, N.; Boim, M. A. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am. J. Physiol. Renal Physiol, 2004, 286, F1039-1045.
145. Yamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E. Expression of transforming growth factor-P is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA, 1993, 90, 1814-1818.
146. Kagami, S.; Border, W. A.; Miller, D. E., Noble, N. A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-P expression in rat glomerular mesangial cells. J. Clin. Invest., 1994, 93, 2431-2437.
147. Liebau, M. C.; Lang, D.; Bohm, J.; Endlich, N.; Bek, M. J.; Witherden, I.; Mathieson, P. W.; Saleem, M. A.; Pavenstadt, H.; Fischer, K. G. Functional expression of the renin-angiotensin system in human podocytes. Am. J. Physiol. Renal Physiol, 2006, 290, F710-719.
148. Nguyen, G.; Delarue, F.; Burckle, C.; Bouzhir, L.; Giller, T.; Sraer, J. D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest., 2002, 109, 1417-1427.
149. Satofuka, S.; Ichihara, A.; Nagai, N.; Noda, K.; Ozawa, Y.; Fukamizu, A.; Tsubota, K.; Itoh, H.; Oike, Y.; Ishida, S. (Pro) renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes, 2009, 58, 1625-1633.
150. Ichihara, A.; Sakoda, M.; Mito-Kurauchi, A.; Itoh, H. Activated prorenin as a therapeutic target for diabetic nephropathy. Diabetes Res. Clin. Pract., 2008, 82 (Suppl 1), S63-66.
151. Takahashi, H.; Ichihara, A.; Kaneshiro, Y.; Inomata, K.; Sakoda, M.; Takemistu, T.; Nishiyama, A.; Itoh, H. Regression of nephropathy developed in diabetes by (Pro) renin receptor blockade. J. Am. Soc. Nephrol, 2007, 18, 2054-2061.
152. Cooper, M. E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia, 2001, 44, 1957-1972.
153. Wolf, G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur. J. Clin. Invest., 2004, 34, 785-796.
154. He, W.; Miao, F. J-P; Lin, D. C-H.; Schwandner, R. T.; Wang, Z.; Gao, J.; Chen, J-L.; Tian, H.; Ling, L. Citric acid cycle intermediates as ligands for G-protein-couple receptors. Nature, 2004, 429, 188-193.
155. Toma, I.; Kang, J. J.; Sipos, A.; Vargas, S.; Bansal, E.; Hanner, F.;
156. Peti-Peterdi, J.; Kang, J. J., Toma, I. Activation of renal renninangiotensin system in diabetes - new concepts. Nephrol. Dial. Transplant., 2008, 23, 3047-3049.
157. Yamazaki, T.; Komuro, I.; Yazaki, Y. Role of the renin-angiotensin system in cardiac hypertrophy. Am. J. Cardiol., 1999, 83, 53H-57H.
158. Zou, Y.; Akazawa, H.; Qin, Y.; Sano, M.; Takano, H.; Minamino, T.; Makita, N.; Iwanaga, K.; Zhu, W.; Kudoh, S.; Toko, H.; Tamura, K.; Kihara, M.; Nagai, T.; Fukamizu, A.; Umemura, S.; Iiri, T.; Fujita, T.; Komuro, I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol., 2004, 6, 499-506.
159. Yatabe, J.; Sanada, H.; Yatabe, M. S.; Hashimoto, S.; Yoneda, M.; Felder, R. A.; Jose, P. A.; Watanabe, T. Angiotensin II type 1 receptor blocker attenuates the activation of ERK and NADPH oxidase by mechanical strain in mesangial cells in the absence of angiotensin II. Am. J. Physiol. Renal. Physiol., 2009, 296, F1052-1060.
160. Swaminathan, S.; Shah, S. V. Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease. Curr. Opin. Nephrol. Hypertens., 2008, 17, 143-148.
161. Balakumar, P.; Arora, M. K.; Reddy, J.; Anand-Srivastava, M. B. Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted signaling mechanism. J. Cardiovasc. Pharmacol., 2009, 54, 129-138.
162. Turgut, F.; Bolton, W. K. Potential New therapeutic agents for diabetic kidney disease. Am. J. Kid. Dis., 2010, 55, 928-940.
163. Decleves, A. E.; Sharma, K. New Pharmacological treatments for improvement of renal outcomes in diabetes. Nat. Rev. Nephrol., 2010, 6, 371-380.